Español 
Deutsch 
Français 
MSCI World Index (MSC)
NASDAQ Composite (NASDAQ)
FTSE China A50 Index (FGI)
STOXX Europe 600 (SIX)
Nikkei 300 (OSA)
NIFTY 50 (NSE)
DAX Performance Index (XETRA)
FTSE 100 (FGI)
CAC 40 (EURONEXT)
CV Sciences, Inc. (CVSI)
USD0.02
0.00 (-9.69%)
US OTC Healthcare Drug Manufacturers - Specialty & Generic
Address
10070 Barnes Canyon Road 92121
San Diego, CA, US
San Diego, CA, US
CEO
Joseph D. Dowling
Website
cvsciences.com
IPO
2013-02-12
CIK 1510964 ISIN US1266541028
Description
CV Sciences, Inc. functions as a life sciences organization primarily operating across North America. Its business activities are organized into two distinct divisions: Consumer Products and Specialty Pharmaceutical. The Consumer Products division focuses on the creation, manufacturing, and commercialization of plant-derived dietary supplements and cannabidiol (CBD) products sourced from hemp. These offerings are marketed under various brand identities including PlusCBD, ProCBD, HappyLane, CV Acute, CV Defense, and PlusCBD Pet. They serve a wide array of health and wellness sectors such as nutraceuticals, personal care, specialty food items, and pet products. The company distributes these goods through its own digital platforms, other online retailers, a network of chosen distributors, and traditional brick-and-mortar stores. In contrast, the Specialty Pharmaceutical division is dedicated to the research, advancement, and eventual market launch of cannabinoids for the treatment of specific medical conditions. A key project in this segment involves the drug candidate CVSI-007, an innovative combination of CBD and nicotine designed to combat smokeless tobacco use and dependence. Established in 2010, the company was initially known as CannaVest Corp. before officially adopting the name CV Sciences, Inc. in January 2016. Its main corporate offices are located in San Diego, California.
Market Cap & Enterprise Value
Merger & Acquisition History
No mergers or acquisitions recorded for this company.
Technical Outlook
Loading outlook…
Loading forecast...
Signal Summary
Loading…
| Indicator | 1D | 1W | 2W | 3W | 1M |
|---|
Each column is computed on that timeframe's candles (1D = daily, 1W ≈ weekly, 1M ≈ monthly), not on the same last day. ▲ bullish · ▼ bearish · — neutral. The Net row counts signals per column; hover any cell (or the indicator name) to see the exact rule behind it.
Day Score & sub-scores
Statistical fingerprint & regime detail
Conditional historical analysis
Customize analysis (advanced)
Indicative levels generated algorithmically. Not financial advice.
Risk Profile
Loading risk profile…
Price Chart
USD0.02
0.00 (-9.69%)
Loading historical data…
Volume Profile
Loading…
Liquidity & share structure
Average Volume
718.1K
Beta
0.44
Float Shares
176.78M
Free Float %
91.4%
Price Performance
| 1D | 5D | 1M | 3M | 6M | YTD | 1Y | 3Y | 5Y | 10Y | Max |
|---|---|---|---|---|---|---|---|---|---|---|
| -0.92% | -4.22% | -4.00% | -42.01% | -1.01% | -51.95% | +3.33% | -30.26% | -92.15% | -93.72% | -99.36% |
Rolling Volatility
Loading…
Drawdown
Loading…
Relative Strength
Loading…
Monthly Returns Heatmap
From
To
Loading…
Annual Monthly Returns
Loading…
Daily Returns Distribution
Loading histogram data…
Revenue flow
Revenue by geography
Revenue by segment
From
To
Revenue composition
From
To
By product
By geography
Financial Statements
Select metrics from the tables below to build your comparison.
Income Statement
Balance Sheet
Cash Flow Statement
Key Metrics
Financial Ratios
Employees
Financial Growth (CAGR)
Market Data
Analyst Consensus (4 ratings, all time)
Hold
Price Targets & DCF
Current price
0.02
Ratings Trend (MoM)
0% Bullish
| Rating | 2024-11 | Change |
|---|---|---|
| Strong Buy | 0 | 0 |
| Buy | 0 | 0 |
| Hold | 1 | 0 |
| Sell | 0 | 0 |
| Strong Sell | 0 | 0 |
Quality scores
Altman Z-Score
-16.96
Distress
Piotroski F-Score
2 / 9
Weak
MOAT Score
2 / 10
No MOAT
Composite Rating
D+
Overall Score
1 / 5
Low
DCF Score
1 / 5
Low
ROE Score
1 / 5
Low
ROA Score
1 / 5
Low
D/E Score
1 / 5
Low
P/E Score
1 / 5
Low
P/Book Score
1 / 5
Low
Operational MOAT
✗ Below peers
-
Revenue growth Drug Manufacturers - Specialty & Generic: +6.8%-12.2% Q1'26: -100.0% (vs Q1'25)
-
EPS growth Drug Manufacturers - Specialty & Generic: +16.5%+61.8% ★ Q1'26: -466.7% (vs Q1'25)
-
FCF margin FCF growth · Drug Manufacturers - Specialty & Generic: +32.3%-12.1%
-
EBIT margin Drug Manufacturers - Specialty & Generic: +13.0%-7.2%
-
ROIC Drug Manufacturers - Specialty & Generic: +6.5%-35.4% Q1'26: +0.0% (vs Q1'25)
-
Share dilution Drug Manufacturers - Specialty & Generic: +0.0%+4.9% Q1'26: +1.4% (vs Q1'25)
-
Debt / EBITDA Net debt/EBITDA · Drug Manufacturers - Specialty & Generic: -0.10×-2.86× Q1'26: -1.17× (vs Q1'25)
Valuation Multiples
From
To
Price Forecast (3Y)
From
To
Theoretical Return — If Invested Today
* These projections are based on analyst consensus estimates and user-defined valuation multiples. This table is for informational purposes only and does not constitute a recommendation to buy or sell any security. Past performance is not indicative of future results.
Consensus Estimates
| Metric |
Dec 2018 actual |
Dec 2019 actual |
Dec 2020 actual |
Dec 2021 actual |
Dec 2022 actual |
Dec 2023 actual |
Dec 2024 actual |
|---|---|---|---|---|---|---|---|
| Revenue |
48.24M
est: 48.90M (-1.3%)
|
53.70M
est: 55.74M (-3.7%)
|
24.43M
est: 25.78M (-5.3%)
|
20.05M
est: 20.26M (-1.0%)
|
16.21M
est: 16.77M (-3.4%)
|
16.00M
est: 17.14M (-6.6%)
|
15.71M
est: 29.00M (-45.8%)
|
| EBITDA |
10.77M
est: -17.74M (+160.7%)
|
-15.69M
est: -20.22M (+22.4%)
|
-21.72M
est: -9.36M (-132.1%)
|
-14.00M
est: -7.35M (-90.4%)
|
-5.66M
est: -6.09M (+7.0%)
|
3.85M
est: -6.22M (+161.8%)
|
-1.86M
est: -5.60M (+66.9%)
|
| EBIT |
10.25M
est: -20.06M (+151.1%)
|
-17.23M
est: -22.86M (+24.7%)
|
-22.59M
est: -10.58M (-113.6%)
|
-15.50M
est: -8.31M (-86.6%)
|
-6.72M
est: -6.88M (+2.3%)
|
3.61M
est: -7.03M (+151.4%)
|
-2.19M
est: -6.81M (+67.8%)
|
| Net Income |
10.00M
est: 15.80M (-36.7%)
|
-16.61M
est: -9.22M (-80.2%)
|
-22.28M
est: -24.58M (+9.3%)
|
-15.55M
est: -15.80M (+1.6%)
|
-8.21M
est: -12.29M (+33.2%)
|
3.10M
est: -7.02M (+144.2%)
|
-2.39M
est: -1.84M (-29.9%)
|
| SGA |
21.75M
est: 43.75M (-50.3%)
|
46.45M
est: 49.87M (-6.8%)
|
30.66M
est: 23.07M (+32.9%)
|
25.88M
est: 18.12M (+42.8%)
|
12.09M
est: 15.01M (-19.4%)
|
9.49M
est: 15.34M (-38.1%)
|
9.24M
est: 21.87M (-57.8%)
|
| EPS |
0.09
est: 0.09 (+0.0%)
|
-0.17
est: -0.05 (-223.8%)
|
-0.22
est: -0.14 (-57.1%)
|
-0.14
est: -0.09 (-55.6%)
|
-0.06
est: -0.07 (+15.0%)
|
0.02
est: -0.04 (+150.3%)
|
-0.01
est: -0.01 (-36.0%)
|
Historical Ratings (3M)
| Date | Rating | Overall | DCF | ROE | ROA | D/E | P/E | P/B |
|---|---|---|---|---|---|---|---|---|
| 2026-05-11 | D+ | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-05-08 | D+ | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-05-07 | D+ | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-05-06 | D+ | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-05-05 | D+ | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-05-04 | D+ | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-05-01 | D+ | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-04-30 | D+ | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-04-29 | D+ | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-04-28 | D+ | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-04-27 | D+ | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-04-24 | D+ | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-04-23 | D+ | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-04-22 | D+ | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-04-21 | D+ | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-04-20 | D+ | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-04-17 | D+ | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-04-16 | D+ | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 |
Owner Earnings
Owner's Earnings (history)
From
To
Owner alignment
Owner's Earnings TTM
-786.3K
OE per share TTM
0.00
Owner's Yield
-14.39%
Maintenance CapEx ratio
—
Maint CapEx / Avg PPE
14.1%
Ownership Overview
Ownership breakdown
Ownership breakdown not available.
At a glance
Institutional holders
—
Total invested
—
Insider transactions (90d)
0
Beneficial owners (>5%)
13
Beneficial owners (>5%)
| # | Reporting person | Amount owned | % of class | Sole voting | Shared voting | Sole dispositive | Shared dispositive | Type | Citizenship | Filing date | SEC filing |
|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | Mackay Ventures, LLC | 8.43M | 24.00% | 618.6K | 7.81M | 618.6K | 7.81M | OO | Utah | 2015-08-25 | ↗ |
| 2 | Michael Joseph Mona, Jr. | 7.50M | 12.50% | 45.00M | 3.00M | 4.50M | 3.00M | IN | United States | 2016-10-18 | ↗ |
| 3 | Mai Dun Limited, LLC | 6.68M | 19.00% | 5.46M | 1.21M | 5.46M | 1.21M | OO | Nevada | 2015-08-25 | ↗ |
| 4 | Bart Mackay | 6.26M | 12.00% | 175.0K | 6.08M | 175.0K | 10.00 | IN | United States | 2016-07-26 | ↗ |
| 5 | Michael Mona, III | 5.42M | 5.76% | 4.67M | 750.0K | 4.67M | 10.00 | IN | United States | 2018-06-08 | ↗ |
| 6 | Rhonda Mona | 3.82M | 4.20% | — | 3.82M | — | — | IN | United States | 2017-06-01 | ↗ |
| 7 | Roen Ventures, LLC | 2.42M | 6.90% | 2.42M | — | 2.42M | — | OO | Nevada | 2015-08-25 | ↗ |
| 8 | Michael Mona III | 2.36M | 4.50% | 2.36M | — | 2.36M | — | IN | United States | 2016-07-25 | ↗ |
| 9 | Cross & Company | 1.65M | 4.11% | 1.65M | — | 1.65M | — | CO | Nevada | 2016-03-25 | ↗ |
| 10 | Mercia Holdings, LLC | 1.21M | 3.50% | — | 1.21M | — | 1.21M | OO | Nevada | 2015-08-25 | ↗ |
| 11 | PhytoSPHERE Systems, LLC | 1.00M | 11.20% | 1.00M | — | 1.00M | — | OO | Delaware | 2013-04-22 | ↗ |
| 12 | Aegean Limited, LLC | 824.2K | 0.90% | 824.2K | — | 824.2K | 824.2K | OO | United States | 2017-06-01 | ↗ |
| 13 | Medical Marijuana, Inc. | 720.0K | 9.10% | 720.0K | — | 720.0K | — | CO | Oregon | 2013-02-12 | ↗ |
Institutional Activity (13F)
Institutional ownership trend
Institutional history not available.
Top institutional holders
Top holders not available.
ETF Ownership
Top ETFs holding this stock
This company is not held by any ETF in our universe.
Insider Activity
Insider Activity — Latest Quarter
Ratio by transactions
0.00
Bearish
Buys
4
Sells
0
Shares acquired
6.35M
Shares disposed
—
Cash buys
—
Cash sales
—
Net activity
+6,350,000
Insider buys vs sells (history)
From
To
Recent insider transactions
From
To
| Date | Person | Role | Transaction | A/D | Security | Shares | Price | Value | Owned after | D/I | Filing |
|---|---|---|---|---|---|---|---|---|---|---|---|
| 2025-02-18 | McCorkle William | Director | A-Award | A | Stock Optoin (right to buy) | 500,000 | 0.04 | 18.7K | 500,000 | D | ↗ |
| 2025-02-18 | Grasser Joerg | Officer | A-Award | A | Employee Stock Option (right to buy) | 2,350,000 | 0.04 | 88.1K | 2,350,000 | D | ↗ |
| 2025-02-18 | Dowling Joseph D | Director / Officer | A-Award | A | Employee Stock Option (right to buy) | 3,000,000 | 0.04 | 112.5K | 3,000,000 | D | ↗ |
| 2025-02-18 | Corroon James Michael Jr. | Director | A-Award | A | Stock Option (right to buy) | 500,000 | 0.04 | 18.8K | 500,000 | D | ↗ |
| 2024-06-20 | McCorkle William | Director | A-Award | A | Stock Option (right to buy) | 500,000 | 0.05 | 27.0K | 500,000 | — | ↗ |
| 2024-06-20 | Grasser Joerg | Officer | A-Award | A | Employee Stock Option (right to buy) | 2,350,000 | 0.05 | 126.9K | 2,350,000 | — | ↗ |
| 2024-06-20 | Dowling Joseph D | Director / Officer | A-Award | A | Employee Stock Option (right to buy) | 3,000,000 | 0.05 | 162.0K | 3,000,000 | — | ↗ |
| 2024-06-20 | Corroon James Michael Jr. | Director | A-Award | A | Stock Option (right to buy) | 500,000 | 0.05 | 27.0K | 500,000 | — | ↗ |
| 2023-03-15 | Grasser Joerg | Officer | A-Award | A | Employee Stock Option (right to buy) | 1,250,000 | 0.04 | 50.0K | 1,250,000 | — | ↗ |
| 2023-03-15 | Dowling Joseph D | Director / Officer | A-Award | A | Employee Stock Option (right to buy) | 2,500,000 | 0.04 | 100.0K | 2,500,000 | — | ↗ |
| 2022-10-21 | McCorkle William | Director | A-Award | A | Employee Stock Option (right to buy) | 500,000 | 0.00 | — | 500,000 | — | ↗ |
| 2022-08-12 | Corroon James Michael Jr. | Director | A-Award | A | Employee Stock Option (right to buy) | 500,000 | 0.03 | 16.3K | 500,000 | — | ↗ |
| 2022-07-21 | Corroon James Michael Jr. | Director | — | D | Common Stock | 0 | 0.00 | — | 1,000 | — | ↗ |
| 2022-03-30 | Grasser Joerg | Officer | D-Return | D | Employee Stock Option (right to buy) | 250,000 | 0.00 | — | 0 | — | ↗ |
| 2022-03-30 | Dowling Joseph D | Director / Officer | D-Return | D | Employee Stock Option (right to buy) | 1,500,000 | 0.59 | 885.0K | 0 | — | ↗ |
| 2021-06-02 | MAROON JOSEPH C MD | Director | A-Award | A | Stock Option (right to buy) | 275,000 | 0.39 | 107.3K | 275,000 | — | ↗ |
| 2021-06-02 | GRAHAM TERRI F | Director | A-Award | A | Stock Option (right to buy) | 275,000 | 0.39 | 107.3K | 275,000 | — | ↗ |
| 2021-06-02 | BLAKE PAUL | Director | A-Award | A | Stock Option (right to buy) | 275,000 | 0.39 | 107.3K | 275,000 | — | ↗ |
| 2021-06-02 | Altman Elizabeth Ann | Director | A-Award | A | Stock Option (right to buy) | 275,000 | 0.39 | 107.3K | 275,000 | — | ↗ |
| 2021-05-21 | MAROON JOSEPH C MD | Director | P-Purchase | A | Common Stock | 50,000 | 0.38 | 19.0K | 791,116 | — | ↗ |
| 2021-03-09 | MacKay Douglas Jesse | Officer | A-Award | A | Employee Stock Option (right to buy) | 400,000 | 0.59 | 236.0K | 400,000 | — | ↗ |
| 2021-03-09 | Grasser Joerg | Officer | A-Award | A | Employee Stock Option (right to buy) | 750,000 | 0.59 | 442.5K | 750,000 | — | ↗ |
| 2021-03-09 | Dowling Joseph D | Director / Officer | A-Award | A | Employee Stock Option (right to buy) | 1,500,000 | 0.59 | 885.0K | 1,500,000 | — | ↗ |
| 2021-01-15 | Mona Michael Joseph Jr | 10% Owner | S-Sale | D | Common Stock | 16,600 | 0.66 | 10.9K | 1,812,060 | — | ↗ |
| 2021-01-14 | Mona Michael Joseph Jr | 10% Owner | S-Sale | D | Common Stock | 100,000 | 0.63 | 63.0K | 1,828,660 | — | ↗ |
| 2021-01-13 | Mona Michael Joseph Jr | 10% Owner | S-Sale | D | Common Stock | 100,000 | 0.61 | 61.1K | 1,928,660 | — | ↗ |
| 2021-01-07 | Mona Michael Joseph Jr | 10% Owner | S-Sale | D | Common Stock | 75,140 | 0.57 | 42.9K | 2,028,660 | — | ↗ |
| 2021-01-06 | Mona Michael Joseph Jr | 10% Owner | S-Sale | D | Common Stock | 75,000 | 0.56 | 41.6K | 2,103,800 | — | ↗ |
| 2020-12-02 | Mona Michael Joseph Jr | 10% Owner | S-Sale | D | Common Stock | 42,800 | 0.61 | 26.2K | 2,178,800 | — | ↗ |
| 2020-12-01 | Mona Michael Joseph Jr | 10% Owner | S-Sale | D | Common Stock | 57,400 | 0.61 | 35.2K | 2,221,600 | — | ↗ |
| 2020-11-30 | Mona Michael Joseph Jr | 10% Owner | S-Sale | D | Common Stock | 400,000 | 0.59 | 234.5K | 2,279,000 | — | ↗ |
| 2020-07-30 | Mona Michael Joseph Jr | 10% Owner | S-Sale | D | Common Stock | 58,535 | 0.58 | 34.0K | 174,662 | — | ↗ |
| 2020-07-29 | Mona Michael Joseph Jr | 10% Owner | S-Sale | D | Common Stock | 50,000 | 0.58 | 29.2K | 233,197 | — | ↗ |
| 2020-06-16 | MCNULTY JAMES A | Director | A-Award | A | Common Stock | 230,000 | 0.75 | 172.5K | 230,000 | — | ↗ |
| 2020-06-16 | MAROON JOSEPH C MD | Director | A-Award | A | Common Stock | 190,000 | 0.75 | 142.5K | 190,000 | — | ↗ |
| 2020-06-16 | GRAHAM TERRI F | Director | A-Award | A | Common Stock | 150,000 | 0.75 | 112.5K | 150,000 | — | ↗ |
| 2020-06-16 | BLAKE PAUL | Director | A-Award | A | Common Stock | 150,000 | 0.75 | 112.5K | 150,000 | — | ↗ |
| 2020-06-16 | Altman Elizabeth Ann | Director | A-Award | A | Common Stock | 150,000 | 0.75 | 112.5K | 150,000 | — | ↗ |
| 2020-06-10 | Mona Michael Joseph Jr | 10% Owner | S-Sale | D | Common Stock | 8,803 | 0.80 | 7.0K | 283,197 | — | ↗ |
| 2020-05-22 | Mona Michael Joseph Jr | 10% Owner | S-Sale | D | Common Stock | 30,000 | 0.80 | 24.0K | 292,000 | — | ↗ |
| 2020-05-14 | BLAKE PAUL | Director | P-Purchase | A | Common Stock | 12,801 | 0.39 | 5.0K | 12,801 | — | ↗ |
| 2020-05-05 | Mona Michael Joseph Jr | 10% Owner | S-Sale | D | Common Stock | 136,285 | 0.47 | 64.2K | 2,679,000 | — | ↗ |
| 2020-05-04 | Mona Michael Joseph Jr | 10% Owner | S-Sale | D | Common Stock | 109,239 | 0.48 | 52.1K | 2,815,285 | — | ↗ |
| 2020-05-01 | Mona Michael Joseph Jr | 10% Owner | S-Sale | D | Common Stock | 42,790 | 0.48 | 20.7K | 2,924,524 | — | ↗ |
| 2020-04-30 | Mona Michael Joseph Jr | 10% Owner | S-Sale | D | Common Stock | 16,840 | 0.51 | 8.7K | 2,967,314 | — | ↗ |
| 2020-04-29 | Mona Michael Joseph Jr | 10% Owner | S-Sale | D | Common Stock | 84,575 | 0.53 | 45.0K | 2,984,154 | — | ↗ |
| 2020-04-28 | Mona Michael Joseph Jr | 10% Owner | S-Sale | D | Common Stock | 5,650 | 0.54 | 3.1K | 3,068,729 | — | ↗ |
| 2020-04-27 | Mona Michael Joseph Jr | 10% Owner | S-Sale | D | Common Stock | 207,226 | 0.52 | 107.9K | 3,074,379 | — | ↗ |
| 2020-04-23 | Mona Michael Joseph Jr | 10% Owner | S-Sale | D | Common Stock | 42,774 | 0.51 | 22.0K | 3,281,605 | — | ↗ |
| 2020-04-22 | Mona Michael Joseph Jr | 10% Owner | S-Sale | D | Common Stock | 278,421 | 0.50 | 139.7K | 3,324,379 | — | ↗ |
| 2020-04-21 | Mona Michael Joseph Jr | 10% Owner | S-Sale | D | Common Stock | 77,200 | 0.52 | 40.5K | 3,602,800 | — | ↗ |
| 2020-03-26 | Mona Michael Joseph Jr | 10% Owner | S-Sale | D | Common Stock | 25,000 | 0.70 | 17.5K | 322,000 | — | ↗ |
| 2020-03-20 | MacKay Douglas Jesse | Officer | — | D | Employee Stock Option (right to buy) | 250,000 | 4.67 | 1.17M | 0 | — | ↗ |
| 2020-03-20 | Grasser Joerg | Officer | A-Award | A | Employee Stock Option (right to buy) | 750,000 | 0.33 | 247.5K | 750,000 | — | ↗ |
| 2020-03-20 | Dowling Joseph D | Director / Officer | A-Award | A | Employee Stock Option (right to buy) | 1,500,000 | 0.33 | 495.0K | 1,500,000 | — | ↗ |
| 2020-02-14 | Mona Michael Joseph Jr | 10% Owner | S-Sale | D | Common Stock | 45,000 | 0.95 | 42.8K | 347,000 | — | ↗ |
| 2020-02-11 | Mona Michael Joseph Jr | 10% Owner | S-Sale | D | Common Stock | 8,000 | 0.95 | 7.6K | 392,000 | — | ↗ |
| 2020-02-06 | MAROON JOSEPH C MD | Director | P-Purchase | A | Common Stock | 26,000 | 0.94 | 24.4K | 741,116 | — | ↗ |
| 2020-01-20 | Mona Michael Joseph Jr | 10% Owner | S-Sale | D | Common Stock | 80,000 | 1.20 | 96.0K | 400,000 | — | ↗ |
| 2020-01-15 | Mona Michael Joseph Jr | 10% Owner | S-Sale | D | Common Stock | 50,000 | 1.20 | 60.0K | 480,000 | — | ↗ |
| 2020-01-14 | Mona Michael Joseph Jr | 10% Owner | S-Sale | D | Common Stock | 50,000 | 1.05 | 52.5K | 580,000 | — | ↗ |
| 2020-01-09 | Mona Michael Joseph Jr | 10% Owner | S-Sale | D | Common Stock | 25,221 | 1.00 | 25.2K | 680,000 | — | ↗ |
| 2020-01-08 | Mona Michael Joseph Jr | 10% Owner | S-Sale | D | Common Stock | 18,400 | 1.00 | 18.4K | 705,221 | — | ↗ |
| 2020-01-07 | Mona Michael Joseph Jr | 10% Owner | S-Sale | D | Common Stock | 6,379 | 1.00 | 6.4K | 723,621 | — | ↗ |
| 2019-12-31 | Altman Elizabeth Ann | Director | — | — | — | 0 | 0.00 | — | 0 | — | ↗ |
| 2019-12-27 | Mona Michael III | Director / Officer | M-Exempt | A | Common Stock | 250,000 | 0.40 | 100.0K | 1,230,000 | — | ↗ |
| 2019-12-11 | MAROON JOSEPH C MD | Director | P-Purchase | A | Common Stock | 46,725 | 1.09 | 50.9K | 715,116 | — | ↗ |
| 2019-12-05 | MAROON JOSEPH C MD | Director | P-Purchase | A | Common Stock | 25,000 | 0.98 | 24.5K | 668,391 | — | ↗ |
| 2019-11-08 | Dowling Joseph D | Director / Officer | P-Purchase | A | Common Stock | 15,000 | 1.65 | 24.8K | 15,000 | — | ↗ |
| 2019-11-07 | Grasser Joerg | Officer | P-Purchase | A | Common Stock | 15,000 | 1.49 | 22.3K | 15,000 | — | ↗ |
| 2019-10-24 | Altman Elizabeth Ann | Director | — | D | Employee Stock Option (right to buy) | 109,000 | 2.06 | 224.5K | 0 | — | ↗ |
| 2019-10-21 | BLAKE PAUL | Director | — | D | Common Stock | 0 | 0.00 | — | 0 | — | ↗ |
| 2019-08-22 | GRAHAM TERRI F | Director | — | D | Stock Option (right to buy) | 62,000 | 3.62 | 224.4K | 0 | — | ↗ |
| 2019-03-15 | Grasser Joerg | Officer | A-Award | A | Employee Stock Option (right to buy) | 250,000 | 4.67 | 1.17M | 250,000 | — | ↗ |
| 2019-02-20 | Dowling Joseph D | Director / Officer | A-Award | A | Employee Stock Option (right to buy) | 500,000 | 4.72 | 2.36M | 500,000 | — | ↗ |
| 2019-01-10 | Mona Michael Joseph Jr | 10% Owner | M-Exempt | A | Common Stock | 200,000 | 0.38 | 76.0K | 730,000 | — | ↗ |
| 2018-12-26 | Grasser Joerg | Officer | — | D | Common Stock | 0 | 0.00 | — | 0 | — | ↗ |
| 2018-08-04 | MAROON JOSEPH C MD | Director | — | D | Stock Option (right to buy) | 250,000 | 2.95 | 737.5K | 0 | — | ↗ |
| 2018-06-08 | Mona Michael Joseph Jr | 10% Owner | A-Award | A | Restricted Stock Units | 2,950,000 | 0.00 | — | 2,950,000 | — | ↗ |
| 2018-03-20 | Mona Michael Joseph Jr | 10% Owner | A-Award | A | Employee Stock Option (right to buy) | 1,050,000 | 0.40 | 420.0K | 1,050,000 | — | ↗ |
| 2018-03-20 | Mona Michael III | Director / Officer | A-Award | A | Employee Stock Option (right to buy) | 500,000 | 0.40 | 200.0K | 500,000 | — | ↗ |
| 2018-03-20 | Dowling Joseph D | Officer | A-Award | A | Employee Stock Option (right to buy) | 500,000 | 0.40 | 200.0K | 500,000 | — | ↗ |
| 2018-02-05 | Sligar Gary | Director | A-Award | A | Stock Option (right to buy) | 40,000 | 0.41 | 16.2K | 40,000 | — | ↗ |
| 2018-02-05 | MCNULTY JAMES A | Director | A-Award | A | Stock Option (right to buy) | 40,000 | 0.41 | 16.2K | 40,000 | — | ↗ |
| 2017-12-01 | Schmitz Stephen Martin | Director | A-Award | A | Employee Stock Option (right to buy) | 200,000 | 0.23 | 46.1K | 200,000 | — | ↗ |
| 2017-07-14 | Sligar Gary | Director | A-Award | A | Stock Option (right to buy) | 100,000 | 0.26 | 26.0K | 100,000 | — | ↗ |
| 2017-07-14 | Mona Michael Joseph Jr | Director / Officer / 10% Owner | A-Award | A | Employee Stock Option (right to buy) | 1,500,000 | 0.37 | 552.0K | 1,500,000 | — | ↗ |
| 2017-07-14 | Mona Michael III | Director / Officer | A-Award | A | Employee Stock Option (right to buy) | 1,000,000 | 0.37 | 368.0K | 1,000,000 | — | ↗ |
| 2017-07-14 | Dowling Joseph D | Officer | A-Award | A | Employee Stock Option (right to buy) | 250,000 | 0.37 | 92.0K | 250,000 | — | ↗ |
| 2017-05-16 | Schmitz Stephen Martin | Director | A-Award | A | Employee Stock Option (right to buy) | 250,000 | 0.31 | 76.9K | 250,000 | — | ↗ |
| 2017-05-10 | Schmitz Stephen Martin | Director | — | I | Common Stock | 0 | 0.00 | — | 56,000 | — | ↗ |
| 2017-03-17 | MCNULTY JAMES A | Director | J-Other | A | Common Stock | 1,450,500 | 0.41 | 599.1K | 1,545,500 | — | ↗ |
| 2017-03-15 | Mona Michael Joseph Jr | Director / Officer / 10% Owner | A-Award | A | Employee Stock Option (right to buy) | 200,000 | 0.38 | 76.0K | 200,000 | — | ↗ |
| 2017-03-15 | Mona Michael III | Director / Officer | A-Award | A | Employee Stock Option (right to buy) | 100,000 | 0.38 | 38.0K | 100,000 | — | ↗ |
| 2017-03-15 | Dowling Joseph D | Officer | A-Award | A | Employee Stock Option (right to buy) | 100,000 | 0.38 | 38.0K | 100,000 | — | ↗ |
| 2016-10-05 | Mona Michael Joseph Jr | Director / Officer / 10% Owner | A-Award | A | Employee Stock Option (right to buy) | 1,500,000 | 0.37 | 552.0K | 1,500,000 | — | ↗ |
| 2016-10-05 | Mona Michael III | Director / Officer | A-Award | A | Employee Stock Option (right to buy) | 1,000,000 | 0.37 | 368.0K | 1,000,000 | — | ↗ |
| 2016-10-05 | MCNULTY JAMES A | Director | J-Other | A | Common Stock | 45,000 | 0.41 | 18.2K | 95,000 | — | ↗ |
| 2016-10-05 | Dowling Joseph D | Officer | A-Award | A | Employee Stock Option (right to buy) | 250,000 | 0.37 | 92.0K | 250,000 | — | ↗ |
| 2016-07-06 | Raskin Larry Phillip | Director | A-Award | A | Stock Option (right to buy) | 200,000 | 0.37 | 73.6K | 200,000 | — | ↗ |
| 2016-07-06 | Mackay Bart P | — | P-Purchase | A | Warrants (right to buy) | 100,000 | 0.37 | 36.8K | 100,000 | — | ↗ |
| 2016-07-06 | MCNULTY JAMES A | Director | A-Award | A | Stock Option (right to buy) | 200,000 | 0.37 | 73.6K | 250,000 | — | ↗ |
| 2016-06-02 | Sligar Gary | Director | — | D | Stock Option (right to buy) | 200,000 | 0.37 | 73.6K | 0 | — | ↗ |
| 2016-05-23 | Raskin Larry Phillip | Director | P-Purchase | A | Common Stock | 35,000 | 0.47 | 16.5K | 525,000 | — | ↗ |
| 2016-05-20 | Raskin Larry Phillip | Director | P-Purchase | A | Common Stock | 25,000 | 0.46 | 11.5K | 490,000 | — | ↗ |
| 2016-05-19 | Raskin Larry Phillip | Director | P-Purchase | A | Common Stock | 15,000 | 0.49 | 7.3K | 465,000 | — | ↗ |
| 2016-02-28 | Mackay Bart P | Director | J-Other | D | Common Stock | 1,600,000 | 0.00 | — | 0 | — | ↗ |
| 2016-01-04 | MCNULTY JAMES A | Director | — | D | Common Stock | 0 | 0.00 | — | 50,000 | — | ↗ |
| 2015-12-30 | Mackay Bart P | Director | J-Other | D | Common Stock | 824,164 | 0.59 | 483.0K | 1,600,000 | — | ↗ |
| 2015-12-28 | Mona Michael Joseph Jr | Director / Officer | A-Award | A | Employee Stock Option (right to buy) | 530,000 | 0.16 | 82.2K | 530,000 | — | ↗ |
| 2015-12-28 | Dowling Joseph D | Officer | A-Award | A | Employee Stock Option (right to buy) | 150,000 | 0.16 | 23.3K | 150,000 | — | ↗ |
| 2015-12-17 | Mackay Bart P | Director | A-Award | A | Common Stock | 25,000 | 0.00 | — | 25,000 | — | ↗ |
| 2015-09-23 | Raskin Larry Phillip | Director | A-Award | A | Stock Option (right to buy) | 20,000 | 0.73 | 14.6K | 20,000 | — | ↗ |
| 2015-09-23 | Mona Michael Joseph Jr | Director / Officer | A-Award | A | Employee Stock Option (right to buy) | 1,470,000 | 0.73 | 1.07M | 1,470,000 | — | ↗ |
| 2015-09-23 | Mona Michael III | Officer | A-Award | A | Employee Stock Option (right to buy) | 343,000 | 0.73 | 250.4K | 343,000 | — | ↗ |
| 2015-09-23 | Dowling Joseph D | Officer | A-Award | A | Employee Stock Option (right to buy) | 200,000 | 0.73 | 146.0K | 200,000 | — | ↗ |
| 2015-07-17 | Mackay Bart P | Director | J-Other | D | Common Stock | 7,575,836 | 0.42 | 3.18M | 2,424,164 | — | ↗ |
| 2015-05-21 | Dowling Joseph D | Officer | A-Award | A | Employee Stock Option (right to buy) | 100,000 | 1.39 | 139.0K | 100,000 | — | ↗ |
| 2015-05-07 | Raskin Larry Phillip | Director | A-Award | A | Common Stock | 25,000 | 0.00 | — | 425,000 | — | ↗ |
| 2015-05-05 | Raskin Larry Phillip | Director | A-Award | A | Stock Option (right to buy) | 40,000 | 1.80 | 72.0K | 40,000 | — | ↗ |
| 2015-03-16 | Mackay Bart P | Director | A-Award | A | Common Stock | 25,000 | 0.00 | — | 50,000 | — | ↗ |
| 2015-01-02 | Mona Michael III | Officer | A-Award | A | Common Stock | 250,000 | 0.00 | — | 1,750,000 | — | ↗ |
| 2015-01-01 | Mona Michael III | Officer | P-Purchase | A | Common Stock | 250,000 | 2.36 | 590.0K | 1,750,000 | — | ↗ |
| 2014-12-08 | Mona Michael Joseph Jr | Director / Officer | A-Award | A | Employee Stock Option (right to buy) | 4,000,000 | 2.64 | 10.56M | 4,000,000 | — | ↗ |
| 2014-10-01 | Mona Michael III | Officer | A-Award | A | Common Stock | 250,000 | 0.00 | — | 2,500,000 | — | ↗ |
| 2014-10-01 | Mackay Bart P | Director | A-Award | A | Common Stock | 25,000 | 0.00 | — | 25,000 | — | ↗ |
| 2014-10-01 | Dowling Joseph D | Officer | A-Award | A | Employee Stock Option (right to buy) | 600,000 | 2.82 | 1.69M | 600,000 | — | ↗ |
| 2014-06-16 | Dowling Joseph D | Officer | — | — | — | 0 | 0.00 | — | 0 | — | ↗ |
| 2014-05-07 | Sobieski Theodore R | Director | — | — | — | 0 | 0.00 | — | 0 | — | ↗ |
| 2014-05-07 | Raskin Larry Phillip | Director | — | D | Common Stock | 0 | 0.00 | — | 400,000 | — | ↗ |
| 2014-05-03 | Mackay Bart P | Director | J-Other | A | Common Stock | 1,861,759 | 0.00 | — | 5,739,518 | — | ↗ |
| 2014-02-28 | Mona Michael III | Officer | P-Purchase | A | Common Stock | 1,000,000 | 1.00 | 1.00M | 2,250,000 | — | ↗ |
| 2014-01-22 | Mackay Bart P | Director | C-Conversion | A | Common Stock | 10,000,000 | 0.60 | 6.00M | 10,000,000 | — | ↗ |
| 2014-01-15 | Mackay Bart P | Director | P-Purchase | A | Common Stock | 100,000 | 1.00 | 100.0K | 100,000 | — | ↗ |
| 2013-12-06 | Sobieski Theodore R | Director | P-Purchase | A | Common stock | 50,000 | 1.00 | 50.0K | 50,000 | — | ↗ |
| 2013-11-07 | Mackay Bart P | Director | C-Conversion | D | Convertible Promissory Note | 6,000,000 | 0.60 | 3.60M | 0 | — | ↗ |
| 2013-07-25 | Mona Michael III | Officer | — | I | Common Stock | 0 | 0.00 | — | 750,000 | — | ↗ |
| 2013-04-01 | PhytoSPHERE Systems, LLC | 10% Owner | — | D | Common Stock | 0 | 0.00 | — | 1,000,000 | — | ↗ |
| 2013-03-15 | Wilson Edward A | Director | — | — | — | 0 | 0.00 | — | 0 | — | ↗ |
| 2013-03-15 | Sobieski Theodore R | Director | — | — | — | 0 | 0.00 | — | 0 | — | ↗ |
| 2012-11-26 | Mona Michael Joseph Jr | Director | — | — | — | 0 | 0.00 | — | 0 | — | ↗ |
| 2012-11-16 | Mercia Holdings LLC | — | — | D | Common Stock | 0 | 0.00 | — | 2,861,759 | — | ↗ |
Executive team
Top executives
EBIT / Employee
-21.1K
Shares Outstanding
193.46M
Executive compensation
Executive compensation (annual)
| # | Year | Executive | Salary | Bonus | Stock award | Option award | Incentive | Other | Total | % Stock- based |
Filing |
|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | 2025 | Joseph Dowling Chief Executive Officer | 294.0K | — | — | 103.9K | — | 21.0K | 419.0K | 24.81% | ↗ |
| 2 | 2025 | Joerg Grasser Chief Financial Officer | 226.6K | — | — | 81.4K | — | — | 308.0K | 26.44% | ↗ |
| 3 | 2024 | Joseph Dowling Chief Executive Officer | 294.6K | — | — | 148.1K | — | 15.0K | 457.7K | 32.35% | ↗ |
| 4 | 2024 | Joerg Grasser Chief Financial Officer | 227.3K | — | — | 116.0K | — | — | 343.3K | 33.78% | ↗ |
| 5 | 2023 | Joseph Dowling Chief Executive Officer | 295.1K | — | — | 90.1K | — | 18.0K | 403.2K | 22.34% | ↗ |
| 6 | 2023 | Joerg Grasser Chief Financial Officer | 228.0K | — | — | 45.0K | — | — | 273.0K | 16.50% | ↗ |
| 7 | 2022 | Joseph Dowling Chief Executive Officer | 277.9K | — | — | — | — | 21.1K | 299.0K | 0.00% | ↗ |
| 8 | 2022 | Joerg Grasser Chief Financial Officer | 210.4K | — | — | — | — | 100.00 | 210.5K | 0.00% | ↗ |
| 9 | 2021 | Joseph Dowling Chief Executive Officer | 400.5K | — | — | 788.3K | — | 18.0K | 1.21M | 65.32% | ↗ |
| 10 | 2021 | Joerg Grasser Chief Financial Officer | 251.5K | — | — | 394.1K | — | — | 645.7K | 61.04% | ↗ |
| 11 | 2020 | Joseph Dowling Chief Executive Officer | 362.1K | — | — | 484.5K | — | 16.5K | 863.1K | 56.13% | ↗ |
| 12 | 2020 | Joerg Grasser Chief Financial Officer | 214.7K | — | — | 267.9K | — | — | 482.7K | 55.51% | ↗ |
| 13 | 2020 | Dr. Douglas MacKay Senior Vice President of Scientific and Regulatory Affairs | 195.2K | — | — | 141.2K | — | — | 336.4K | 41.97% | ↗ |
| 14 | 2019 | Joseph Dowling Chief Executive Officer | 480.8K | — | — | 2.06M | 210.0K | 18.0K | 2.77M | 74.38% | ↗ |
| 15 | 2019 | Michael Mona, III Former Chief Operating Officer | 390.4K | — | — | 1.13M | — | 18.0K | 1.54M | 73.48% | ↗ |
| 16 | 2019 | Joerg Grasser Chief Financial Officer | 269.2K | — | — | 993.2K | 120.0K | — | 1.38M | 71.84% | ↗ |
| 17 | 2019 | Dr. Douglas MacKay Senior Vice President of Scientific and Regulatory Affairs | 192.3K | — | — | 993.7K | 60.0K | — | 1.25M | 79.75% | ↗ |
| 18 | 2019 | Michael Mona, Jr. Former Chairman and Chief Executive Officer | — | — | — | — | — | — | — | — | ↗ |
| 19 | 2018 | Michael Mona, Jr. Former Chairman and Chief Executive Officer | 398.7K | — | 6.31M | 280.1K | 200.0K | 35.8K | 7.23M | 91.22% | ↗ |
| 20 | 2018 | Joerg Grasser Chief Accounting Officer | 3.4K | — | — | 813.1K | — | — | 816.5K | 99.58% | ↗ |
| 21 | 2018 | Joerg Grasser Chief Financial Officer | 3.4K | — | — | 813.1K | — | — | 816.5K | 99.58% | ↗ |
| 22 | 2018 | Joseph Dowling Chief Executive Officer | 397.6K | — | — | 133.4K | 200.0K | 18.0K | 749.0K | 17.81% | ↗ |
| 23 | 2018 | Joseph Dowling Chief Executive Officer and Chief Financial Officer | 397.6K | — | — | 133.4K | 185.0K | 18.0K | 734.0K | 18.17% | ↗ |
| 24 | 2018 | Michael Mona, III Chief Operating Officer | 347.6K | — | — | 133.4K | 185.0K | 15.8K | 681.8K | 19.56% | ↗ |
| 25 | 2018 | Michael Mona, III Former Chief Operating Officer | 347.6K | — | — | 133.4K | 175.0K | 15.8K | 671.8K | 19.85% | ↗ |
| 26 | 2017 | Michael Mona, Jr. Chairman and CEO | 330.0K | 390.5K | — | 313.2K | 403.4K | 30.7K | 1.47M | 21.34% | ↗ |
| 27 | 2017 | Michael Mona, Jr. Former Chairman and Chief Executive Officer | 330.0K | — | — | 716.6K | 390.5K | 30.7K | 1.47M | 48.82% | ↗ |
| 28 | 2017 | Michael Mona, III Chief Operating Officer | 225.0K | — | — | 289.7K | 175.0K | 15.8K | 705.5K | 41.07% | ↗ |
| 29 | 2017 | Joseph Dowling Chief Executive Officer and Chief Financial Officer | 275.0K | — | — | 166.5K | 175.0K | 18.0K | 634.5K | 26.24% | ↗ |
| 30 | 2017 | Joseph Dowling Chief Financial Officer | 275.0K | 175.0K | — | 92.4K | 74.1K | 18.0K | 634.5K | 14.57% | ↗ |
| 31 | 2017 | Joerg Grasser Chief Accounting Officer | — | — | — | — | — | — | — | — | ↗ |
| 32 | 2016 | Michael Mona, Jr. Chairman and CEO | 314.8K | 20.0K | — | — | 485.4K | 47.6K | 867.8K | 0.00% | ↗ |
| 33 | 2016 | Michael Mona Jr. Chairman, CEO | 314.8K | 20.0K | — | — | 485.4K | 47.6K | 867.8K | 0.00% | ↗ |
| 34 | 2016 | Michael Mona, III Chief Operating Officer | 202.2K | 20.0K | — | — | 314.7K | 37.9K | 574.8K | 0.00% | ↗ |
| 35 | 2016 | Michael Mona III Chief Operating Officer | 202.2K | 20.0K | — | — | 314.7K | 37.9K | 574.8K | 0.00% | ↗ |
| 36 | 2016 | Joseph Dowling Chief Financial Officer and Secretary | 262.3K | 20.0K | — | — | 98.7K | 10.5K | 391.6K | 0.00% | ↗ |
| 37 | 2016 | Joseph Dowling Chief Financial Officer | 262.3K | 20.0K | — | — | 98.7K | 10.5K | 391.6K | 0.00% | ↗ |
| 38 | 2015 | Michael Mona Jr. Chairman, CEO | 300.0K | 15.0K | — | 790.7K | — | — | 1.11M | 71.51% | ↗ |
| 39 | 2015 | Michael Mona, Jr. President, CEO | 300.0K | 15.0K | — | 790.7K | — | — | 1.11M | 71.51% | ↗ |
| 40 | 2015 | Michael Mona, III VP, Operations (now COO) | 180.0K | 15.0K | 590.0K | 184.0K | — | — | 969.0K | 79.88% | ↗ |
| 41 | 2015 | Michael Mona III Chief Operating Officer | 180.0K | 15.0K | 590.0K | 184.0K | — | — | 969.0K | 79.88% | ↗ |
| 42 | 2015 | Joseph Dowling Chief Financial Officer and Secretary | 215.4K | 15.0K | — | 240.3K | — | — | 470.7K | 51.06% | ↗ |
| 43 | 2014 | Michael Mona, Jr. President, CEO | 209.5K | 10.0K | — | 8.32M | — | — | 8.54M | 97.43% | ↗ |
| 44 | 2014 | Michael Mona, Jr. Chairman, CEO | 209.5K | 10.0K | — | 8.32M | — | — | 8.54M | 97.43% | ↗ |
| 45 | 2014 | Michael Mona, III VP, Operations (now COO) | 137.8K | 10.0K | 705.0K | 1.15M | — | — | 2.00M | 92.62% | ↗ |
| 46 | 2014 | Michael Mona, III VP, Operations | 137.8K | 10.0K | 705.0K | 1.15M | — | — | 2.00M | 92.62% | ↗ |
| 47 | 2014 | Joseph Dowling Chief Financial Officer and Secretary | 100.0K | 10.0K | — | 1.51M | — | — | 1.62M | 93.20% | ↗ |
| 48 | 2013 | Michael Mona, Jr. Chairman, CEO | 45.9K | 10.0K | — | — | — | 7.5K | 63.4K | 0.00% | ↗ |
| 49 | 2013 | Michael Mona, Jr. | 45.9K | 10.0K | — | — | — | 7.5K | 63.4K | 0.00% | ↗ |
| 50 | 2013 | Michael Mona, III VP, Operations | 44.8K | 10.0K | — | — | — | — | 54.8K | 0.00% | ↗ |
| 51 | 2013 | Michael Mona, III H.J. Cole | 44.8K | 10.0K | — | — | — | — | 54.8K | 0.00% | ↗ |
| 52 | 2013 | Joseph Dowling Chief Financial Officer and Secretary | — | — | — | — | — | — | — | — | ↗ |
| 53 | 2012 | H.J. Cole | — | — | — | — | — | — | — | — | ↗ |
| 54 | 2012 | Michael Mona, III H.J. Cole | — | — | — | — | — | — | — | — | ↗ |
| 55 | 2012 | Michael Mona, Jr. | — | — | — | — | — | — | — | — | ↗ |
CEO compensation breakdown
Proxy statements
Proxy statements (DEF 14A)
Recent SEC filings
Executive team
| Name | Title | Compensation | Gender |
|---|---|---|---|
| Joseph D. Dowling | Chief Executive Officer, Secretary & Director | 315.0K | male |
| Joerg Grasser | Chief Financial Officer | 226.6K | male |
| Alyssa Dunn | Operations Manager | — | female |
| Brendan Hawkins | Investor Relations | — | male |
| Jesse Karagianes | Senior Vice President of Revenue Growth | — | male |
ESG Rating
ESG Score History DRUG MANUFACTURERS - SPECIALTY & GENERIC
Benchmark vs Sector
Senate Trading Activity
No Senate trading activity found for this company.
House Trading Activity
No House trading activity found for this company.
Market share among peers
Peer comparison — filtered group (TTM)
Your opinion
Share your view on this stock and instantly see how the community has voted over the last 6 months.
Community Opinion for CVSI
Short-term intention
Target Price Distribution
These are community opinions and do not constitute buy or sell advice to act on. The results shown are based on aggregated opinions and are not an investment recommendation, nor do they intend to influence any investment decision.
